Gadolinium

DB12091ApprovedInvestigationalWithdrawnSmall molecule

Gadolinium is under investigation in Hypertension, ACUTE KIDNEY INJURY, and Chronic Kidney Disease. Gadolinium has been investigated for the basic science of CAD, Multiple Sclerosis, and Coronary Artery Disease.

Mechanism: Pharmacologically active on Extracellular calcium-sensing receptor and Piezo-type mechanosensitive ion channel component 1
Curator reviewed
Formula / weight: Gd · 157.25 g/mol (avg)
Also known as: Gd

Resolves to

Compound

UNIIAU0V1LM3JTCAS7440-54-2ChEBI33375PubChem23982

Clinical / RWD

RxNorm1310171

Structure

InChIKeyUIWYJDYFSGRHKR-UHFFFAOYSA-NSMILES[Gd]

Targets

P41180CASRQ92508PIEZO1

What you can answer from here — as of September 23, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

92Clinical trialsPhase, status and sponsor resolved per trial

5+ReferencesStructured and connected to the statements they support

Which drugs share a target with Gadolinium, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account